The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PEN | +19.94% | +6.57% | +1.28% | +578% |
| S&P | +13.19% | +87.83% | +13.42% | +244% |
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.
The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $354.69M | 17.8% |
| Gross Profit | $237.99M | 18.9% |
| Gross Margin | 67.10% | 0.6% |
| Market Cap | $9.88B | 30.9% |
| Market Cap / Employee | $2.20M | 0.0% |
| Employees | 4.5K | 7.1% |
| Net Income | $45.85M | 55.3% |
| EBITDA | $51.33M | 29.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $321.03M | 14.5% |
| Accounts Receivable | $183.43M | 4.2% |
| Inventory | 432.4 | 9.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $201.54M | -5.0% |
| Short Term Debt | $15.51M | 7.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 10.18% | 7.8% |
| Return On Invested Capital | 1.13% | -1.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $42.01M | -17.6% |
| Operating Free Cash Flow | $58.26M | 3.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 690.35 | 250.81 | 68.04 | 60.54 | -73.17% |
| Price to Book | 8.25 | 8.94 | 8.19 | 7.63 | 17.41% |
| Price to Sales | 7.76 | 8.45 | 7.87 | 7.46 | 14.11% |
| Price to Tangible Book Value | 9.79 | 10.52 | 9.54 | 8.81 | 15.37% |
| Price to Free Cash Flow TTM | 62.94 | 69.66 | 62.32 | 65.23 | 14.98% |
| Enterprise Value to EBITDA | 180.54 | 227.37 | 212.97 | 189.04 | -1.05% |
| Free Cash Flow Yield | 1.6% | 1.4% | 1.6% | 1.5% | -13.03% |
| Return on Equity | 1.2% | 3.5% | 12.0% | 13.3% | 325.72% |
| Total Debt | $223.39M | $220.66M | $220.53M | $217.05M | -4.25% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
